Kornimate/medical-research-clean huggingface dataset:
evaluation of aesthetic surgical wound closure by a single layer in comparison with traditional multi-layer closure

Conditions: Surgical Wound Closure Technique

Summary: the study is comparing the results of aesthetic surgery wound closure by a single layer versus the traditional multi-layer closure as regards the wound healing time, local wound complications, and the scar formed.

the study puts in comparison the surgical wound closure of aesthetic procedures by single layer sutures technique, involving part of the subcutaneous tissue and the subdermal layer, with the multi-layer traditional closure, which involves subcutaneous layer closure by one or two raws of sutures and skin closure with any type of suturing techniques, then to evaluate the wound healing time, local wound complications, and the scar formed.

Eligibility criteria:
inclusion criteria: * all cases presented for different aesthetic surgery procedures e.g different breast contouring procedures, surgical trunk contouring procedures, brachioplasty, and thigh lifting. no gender discrimination, age between 16-60 years. exclusion criteria: * we excluded cases in age groups beyond that designed for the study, patients with co-morbid conditions that may affect the results of wound healing e.g diabetics. active smokers, trauma patients, or patients that will undergo primary or secondary reconstructive procedures.

Keywords: surgical wound closure subdermal wound suturing traditional wound closure
a study on neoadjuvant therapy for her-2 positive breast cancer and the prognosis by detecting ctcs

Conditions: Breast Neoplasms

Summary: docetaxel plus carboplatin and trastuzumab has been a standard treatment for patients with human epidermal growth factor receptor-2（her-2）positive. the investigators witnessed a higher pathological complete remission(pcr) rate but no obvious increase in cardiac toxicity when used the anthracycline instead of carboplatin. the investigators expect to carry out a large sample size clinical research to optimize the existing therapeutic regimen


Eligibility criteria:
inclusion criteria: * 18≤aged\<70 * pathologic diagnosis of invasive breast cancer，staging ii to iii，the diameters≥2cm indicated by mri or axillary lymph node（+） * immunohistochemical（ihc） positive for 3+ or fish（+） * clear hormone receptor（hr） status * eastern cooperative oncology group(ecog)=0/1 * lvef≥55% * pathologic grading of miller and payne * screening laboratory values with the following parameters：absolute neutrophils acount：≥1500/mm3,total bilirubin:≤2.0×ulm,aspartate transaminase (ast)/alt≤2.5×ulm,platelet≥80000/mm3，serum creatinine≤1.5×ulm * no pregnant or nursing * signed informed consent forms exclusion criteria: * prior exposure to any treatments for breast cancer * inflammatory/bilateral/iv stage breast cancer * poor physical condition * pregnant or nursing * cardiac risk（congestive heart failure、arrhythmia、myocardial infarct、refractory hypertension（systolic pressure\>180mmhg/diastolic pressure\>100mmhg）） * any other cancer within 5 years prior to screening with the exception of cervical carcinoma and non melanoma skin cancer * allergic to chemotherapy drugs
multiomic analysis of traumatic brain injury and hypertension intracranial hemorrhage lesion tissue

Conditions: Brain Injury Traumatic Severe; Intracranial Hemorrhage, Hypertensive

Summary: the goal of this experimental observation study is to figure out differently expressed biomarkers in lesion tissues in traumatic brain injury or hypertension intracranial hemorrhage patients. the main questions it aims to answer is: * which rna, protein and metabolites are differently expressed in lesion tissues? * what molecular mechanism is participated in tbi or ich? participants will be treated by emergency operation, and their lesion tissues will be collected during the operation.


Eligibility criteria:
inclusion criteria: 1. age \>18 and \<65 2. within 12 hours after brain injury 3. gcs ≥3 and ≤8 4. closed brain injury with frontotemporal contusion or basal ganglia intracranial hemorrhage 5. need emergency intracranial hematoma evacuating operation 6. patient's agents are informed and consent the research exclusion criteria: 1. with tbi, stroke, ich or intracranial tumor history 2. death within 24 hours 3. immunosuppression state 4. severe organ dysfunction 5. complicated infective disease 6. pregnant

Keywords: traumatic brain injury hypertensive intracranial hemorrhage multiomic analysis biomarker molecular mechanism
standardized fecal microbiota transplantation for inflammatory bowel disease

Conditions: Inflammatory Bowel Disease; Ulcerative Colitis; Crohn's Disease

Summary: there are many limitations in the current treatments of inflammatory bowel disease (ibd). now the investigators realized that the intestinal microecological is closely associated with the development of ibd. so the standardized fecal microbiota transplantation is considered to be simple but effective emerging therapies for the treatment of ibd. in this project the investigators intend to carry out a single-center, randomized, single-blind clinical intervention study. the investigators will recruit 40 patients with ibd (20 cases of ulcerative colitis and 20 cases of crohn's disease) in china. the patients will be randomly divided into 2 groups, one group will be given treatment of standardized fecal microbiota transplantation, the other will be simply treated with mesalazine, followed up for at least 1 year. the investigators propose to determine the efficiency, durability and safety of standardized fecal microbiota transplantation for ibd treatment.

in this projects the investigators aim to re-establish a gut balance of intestinal microecological through standardized fecal microbiota transplantation for ibd (uc and cd). we will establish a standardized isolation, store, and transportion steps of fecal bacteria from donated fresh stool in the laboratory. then the bacteria will be transplanted to mid-gut by nose-jejunum nutrition tube. patients in this study will be assigned to receive standardized fmt only once or traditional medicine of mesalazine and would be followed up for at least 1 year. the clinical symptoms, sign, blood tests, abdominal ct, endoscopy and questionnaire will be used to assess the efficiency, durability and safety of standardized fmt at the start and end of the projects.

Eligibility criteria:
inclusion criteria: * severe ibd define as hbi score ≥ 9. * moderate ibd define as 7\<hbi \<9 * montreal classification: age \> 14 years old, location l1-3, behavior b1-3. exclusion criteria: * diarrhea activity scores \< 3 * severely active disease with perianal diseases * severely active disease with indication of surgery. * diagnosis as ibd first time or first year. * no history of using 5-asa, biological (antibody), immunomodulatory therapy, corticosteroid therapy

Keywords: standardized fecal microbiota transplantation inflammatory bowel disease ulcerative colitis crohn's disease
the effect of tranexamic acid on intraoperative and post-operative bleeding in functional endoscopic sinus surgery

Conditions: Chronic Sinusitis

Summary: sinus surgery is a common, day surgery procedure performed by general and subspecialty trained otolaryngologists. in most cases, this is a safe surgery with a low incidence of complications. when there is significant bleeding or enough bleeding to obscure important anatomical landmarks, there is a higher chance of complications. these complications can include blindness, meningitis or cerebrospinal fluid leak. our hypothesis is that in patients taking oral tranexamic acid three days before surgery and six days after, there will be less intraoperative bleeding, better surgical visualization and less postoperative bleeding events.


Eligibility criteria:
inclusion criteria: * chronic sinusitis requiring bilateral functional endoscopic sinus surgery * between the ages of 18-65 * willing to comply with standard followup * no coagulopathy * not pregnant exclusion criteria: * pregnant * on anticoagulants within 3 months of the surgery * coagulopathy * \ 65 years of age

Keywords: fess tranexamic acid hemostasis visualization
comparison of %5 dextrose and betamethasone injections in patients with carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: the aim of the study is to compare the effectiveness of ultrasound-guided betamethasone and 5% dextrose injection, which is routinely applied in clinical practice, in patients with mild and moderate carpal tunnel syndrome (cts).

it is planned as an observational, single-center clinical study.a total of 28 patients diagnosed with mild-moderate carpal tunnel syndrome who meet the inclusion criteria will be included in the study.patients who had been experiencing trigger finger symptoms for at least three month and who presented to the gaziler physical medicine and rehabilitation training and research hospital, affiliated with the health sciences university faculty of medicine. patients will be divided into two groups. one group will receive 5% dextrose, the other group will receive 1 session of local injection by mixing celeston chronodose \[1ml/3 mg betamethasone acetate+3,947 mg betamethasone disodium phosphate (equivalent to 3 mg betamethasone)\] and 1 ml 2% prilocaine. evaluations will be made before injection, at weeks 4 and 12.

Eligibility criteria:
inclusion criteria: * paresthesia and pain symptoms in the region corresponding to the distribution of the median nerve * detection of mild or moderate cts by electromyography * one or both of the phalen test and/or tinel sign are positive on physical examination * symptoms have persisted for at least 3 months exclusion criteria: * those diagnosed with polyneuropathy, plexopathy, radiculopathy, thoracic outlet syndrome * having had surgery or any injection for carpal tunnel syndrome within the last year * history of wrist fracture * those with rheumatoid arthritis, uncontrolled diabetes, gout, chronic renal failure, malignancy, active systemic infection * those with cognitive impairment * coagulopathy or bleeding tendency * pregnancy

Keywords: carpal tunnel syndrome betamethasone % 5 dextrose
awake prone positioning of patients suffering community acquired pneumonia requiring nasal high flow therapy

Conditions: Community-acquired Pneumonia

Summary: community acquired pneumonia, in particular when requiring oxygen therapy because of acute hypoxemic respiratory failure and meeting acute respiratory distress syndrome (ards) criteria frequently leads to tracheal intubation and poor outcome. among invasively mechanically ventilated patients with ards and presenting a pao2/fio2 ratio (arterial partial pressure of oxygen to inspired fraction of oxygen) of less than 150 mmhg, the prone position significantly reduces mortality and represents standard care (guérin 2013). among non-intubated covid-19 patients, a subtype of viral community acquired pneumonia, a recent study showed that awake prone positioning reduces the composite outcome of intubation or death among patients requiring nasal high flow therapy. furthermore, it favored weaning of nasal high flow therapy. prone position in patients with non-covid ards treated with high nasal flow was evaluated in 20 patients with predominantly viral pneumonia (ding 2020) and was associated with improved oxygenation. we hypothesize that prone positioning of patients suffering non-covid community acquired pneumonia and undergoing nasal high flow therapy can significantly improve outcome by reducing the need for intubation and associated therapies such as sedation and muscle relaxation.


Eligibility criteria:
inclusion criteria: * adult patients admitted to an intensive care unit or intermediate care unit * suspicion of community acquired pneumonia (at least one of the 3 criteria): fever, cough, purulent expectoration * and abnormalities suggestive of pneumonia by chest x-ray or ct-scan * pao2/fio2 ratio \<300 mmhg (or equivalent spo2/fio2 i.e. \< 315 mmhg) under a minimum gas flow of 30 l/min. * person affiliated to a french social security system or equivalent * informed consent. exclusion criteria: * positive sars-cov2 test within the last 30 days * indication for immediate intubation * patients for whom a "do not intubate" decision has been made * chest trauma or other contraindication to prone position * patients with formal indication for non-invasive ventilation: exacerbation of chronic obstructive pulmonary disease, acute cardiogenic pulmonary oedema. * pregnant or breastfeeding woman * subjects who are under legal protection measure * more than 8h awake prone positioning prior to inclusion * more than 48h since intensive care unit or intermediate care unit admission.
peginterferon beta-1a (biib017) autoinjector pharmacokinetic study in healthy volunteers

Conditions: Healthy; Multiple Sclerosis

Summary: the purpose of this study is to characterize the pharmacokinetic (pk) profile, safety, and tolerability of peginterferon beta-1a (biib017) delivered by the single-use autoinjector or prefilled syringe (pfs) in healthy volunteers to support the development of the autoinjector.

this is a randomized, open-label, 2-sequence, 2-period crossover study that will be conducted at a single site in the united states to characterize the pk profile, safety and tolerability of peginterferon beta-1a delivered by autoinjector or pfs. participants will be randomized in a 1:1 ratio to receive a single dose of peginterferon beta-1a at day 1 delivered by either autoinjector or pfs, followed by a single dose of peginterferon beta 1a delivered by the other device at day 22. the total duration of study participation is up to 3 months for each participant. participants will complete a follow-up visit at day 50 after the end of treatment period.

Eligibility criteria:
key inclusion criteria: 1. must have a body mass index (bmi) of 19 to 29 kg/m\^2, inclusive, and a minimum body weight of 50.0 kg key exclusion criteria: 1. history of any clinically significant laboratory abnormalities, malignancies, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major diseases 2. female subjects who are pregnant or breastfeeding 3. any previous treatment with prescription or investigational pegylated drugs. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: sc peg inteferon pk subcutaneous pegylated autoinjector injectable ms
analgecine for treatment of low back pain

Conditions: Low Back Pain

Summary: the study examines the efficacy and safety of analgecine in the treatment of chronic pain in patients with low back pain for 3 months after surgical treatment. it is a randomized, placebo-controlled, double blind, multi-center phase iii clinical trial. patients with chronic low back pain for 3 months after surgical treatment is recruited (age between 18 and 70; pain visual analysis scale (vas) between 3 and 8). after randomization, subjects are divided into 3 groups: 1) treatment with analgecine (experiment group); 2) treatment with neurotropin (positive control group); 3) placebo group. subjects will be undergone 4 measurement time points on day 0, 7, 14, and 21. in each time points, subjects are required to score their pain with pain vas and to have regular blood, urine, and renal/liver function tests. the changes of the pain vas at day 21 are compared between groups.


Eligibility criteria:
inclusion criteria: * patients with chronic low back pain including patients with spinal degeneration, lumbar herniation, lumbar spinal stenosis, and spondylolisthesis * pain sustained for 3 or more months after surgical treatment. * diagnosis is done by x-ray examination. * the visual analysis scale for pain is between 3 and 8. exclusion criteria: * acute low back pain patients. * allergy to the tested drug. * patients with tuberculosis, tumors, cushing's syndrome, endocrine diseases, neuropathic diseases, psychiatric problems, and serious deficit in heart / liver /renal functions. * patients with pain caused by vascular diseases, stress, or tumors. * patients with pregnancy, lactation, or planning to have pregnancy within 3 months after recruitment. * alcoholic and drug addicted subjects * dementia patients who can cooperate with the study activities. * patients undergone lumber surgery within 3 months at the date of recruitment. * patients who are directly related to the research staff. * patients who have been participated in other drug clinical trial in the past 3 months at the date of the recruitment. * patients who are not fit for the clinical trial based on the research staff observation.
development and validation of a fast, semi-automated hybrid imaging platform to assess coronary atherosclerotic plaque morphology, endothelial shear stress and arterial inflammation: a proof of principle study (valid-pet-ct)

Conditions: Stable Angina; Coronary Artery Disease

Summary: imaging the inside of coronary arteries (intravascular imaging) offers great insight into the assessment and treatment of coronary artery disease. over time, substances such as fat, cholesterol and calcium can build up into 'plaques' in the arteries, causing narrowings or even blockages. these plaques can also rupture, causing cardiovascular events such as heart attacks or strokes. by using ultrasound and infrared technology, intravascular imaging can help assess these plaques, however this is an invasive technique involving angiography. plaque composition, structure and stability can be affected by inflammation and the stress that the arteries are under. the investigators have pioneered novel minimally-invasive methods for modelling arterial stress using computed tomography coronary angiography (ctca), as well as imaging coronary arterial inflammation using a positron emission tomography (pet) scan. before embarking upon a large-scale clinical outcome study to determine whether these novel methods can improve risk prediction, the aim is to perform a proof-of-principle study to further develop our methodology for hybrid image analysis, and to validate this technique against high-resolution intravascular imaging as a surrogate marker of histology.


Eligibility criteria:
inclusion criteria 1. age ≥40 2. stable angina, defined as typical symptoms with evidence of reversible ischemia in non-invasive test and/or documented obstructive coronary artery disease on coronary angiography 3. patient that is willing and can provide written informed consent. exclusion criteria 1. acute coronary syndrome within \<3 months 2. pregnancy 3. estimated glomerular filtration rate (egfr) \<60ml/min/1.73m² 4. previous bypass surgery 5. decompensated heart failure, or left ventricular ejection fraction less than 30% 6. patient allergic to contrast or cannot receive treatment with aspirin, heparin, or thienopyridines 7. anticipated life expectancy \<2 years 8. flow limiting coronary artery disease in the proximal segments of all the 3 epicardial coronaries 9. history of heart transplantation 10. patient that requires surgical revascularization 11. extensive coronary artery disease (i.e., multiple chronic total occlusions) or tortuous coronary anatomy that does not allow assessment of the

Keywords: intravascular ultrasound near infrared spectroscopy positron emission tomography
a study of jnj-75220795 in japanese participants

Conditions: Fatty Liver

Summary: the purpose of this study is to assess the safety and tolerability of single subcutaneous (sc) dose of jnj-75220795 in japanese participants.


Eligibility criteria:
inclusion criteria: * participants with certain genetic predispositions to non-alcoholic fatty liver disease (nafld) determined at screening * presence of liver steatosis at screening * participants on anti-hypertensive and/or lipid lowering medications and/or glucose lowering medications must be on stable dose(s) for at least 4 weeks prior to screening * body mass index between 18 kilograms per meter square (kg/m\^2) and 40 kg/m\^2 inclusive, and body weight stable defined as no more than 5 percent (%) body weight loss or gain within 3 months prior to screening (based on participant's report) and no more than 5% body weight loss or gain from screening to randomization exclusion criteria: * known allergies, hypersensitivity, or intolerance to excipients * history of hepatitis b surface antigen (hbsag) or hepatitis c antibody (anti-hcv) positive, or other clinically active liver disease, or tests positive for hbsag or anti-hcv at screening. and/or history of human immunodeficiency virus (hiv) antibody positive, or tests positive for hiv or syphilis at screening * participants with clinical or biochemical (international normalized ratio \[inr\] greater than \[\>\] 1.2, or platelet count less than \[\<\] lower limits of normal \[lln\]) evidence of hepatic decompensation at screening or baseline * estimated glomerular filtration rate (egfr) by japanese egfr formula below 60 milliliters per minute \[ml/min\] at screening * thyroid stimulating hormone (tsh) levels, free triiodothyronine (ft3) and free thyroxine (ft4) outside normal limits of the clinical laboratory's reference range at screening
5htp regulation of asthma in children

Conditions: Mild or Moderate Asthma With Allergic Sensitization

Summary: the purpose of this study is to learn more about if taking a supplement called 5-hydroxytryptophan (5htp) can improve breathing and anxiety symptoms related to asthma. to help learn more subjects will either be assigned to a group that is taking the supplement (5htp) or a group that is taking a placebo. this will be decided randomly. later in the study subjects will crossover to the other group.there are 5 study visits over the course of about 12 weeks.

the objective of this study is to test the hypothesis that over-the-counter amino acid supplement 5htp (isolated from the plant griffonia simplifolia) reduces human allergic lung responses and consequently improves lung function. the primary outcome is the change in fev1. we anticipate the 5htp at the proposed doses will improve lung function as in preclinical studies that used clinically relevant 5htp. secondary outcomes will be blood eosinophil counts and reduced symptoms for anxiety/depression, as seen in changes in the anxiety-depression scores from questionnaires (ces-dc \& scared). the results from these studies have the transformative potential to influence approaches to improve lung function and asthma-associated anxiety/depression. * aim 1: test that 5htp improves lung function in children with allergic asthma * aim 2: test that 5htp reduces eosinophil numbers in the blood and nasal fluid of patients with asthma from aim 1 * aim 3: test that 5htp decreases lung inflammation, increases cortisol and prolactin without altering systemic plasma concentrations of 5htp, serotonin, 5-hydroxyindoleacetic acid (5-hiaa), and dopamine

Eligibility criteria:
inclusion criteria: * age 8-18 years of age * mild to moderate asthma based on ats guidelines * positive allergy test (positive skin or serum ige) * weight ≥ 70 lbs (32 kg) * ces-dc cut-off ≥ 15 (total score range is 0 to 60) or scared cut-off * 25 (total score range is 0 to 142) * ability to comply with study visits and study procedures * informed consent by participant and if applicable the parent or legal guardian exclusion criteria: * currently taking a ssri * taking a leukotriene inhibitor (montelukast, zileuton) * severe asthma based on ats guidelines * taking a biologic medication (omalizumab, mepolizumab, benralizumab, dupilumab) * medical history of adverse reaction to 5htp * physical findings that would compromise the safety of the study or the quality of the study data